Responses
Regular and Young Investigator Award Abstracts
Immune-Stimulants and Immune Modulators
1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window
Compose a Response to This Article
Other responses
No responses have been published for this article.
